The 3 Amigos...DEP™Docetaxel/Irinotecan/Cabazitaxel are worth billions and billions to Starpharma

The 3 Amigos...DEP™Docetaxel/Irinotecan/Cabazitaxel are worth billions and billions to Starpharma

You just need to look at the less potent molecules without theStarpharma's Drug Enhanced Product (DEP™ to appreciate this

Below are some figures.......which I have posted many times before.......just in case some of the new holders do not know this

Currently there are 85 clinical trials being conducted globally using docetaxel

Currently there are 322 clinical trials being conducted globally using irinotecan

Currently there are 35 clinical trials being conducted globally using cabazitaxel


That's a lot of trials and if they go through to phase 3.......can you imagine how much money is being flushed down the toilet (my opinion of course)

Why would anyone do trials with these drugs and not use DEP™ technology of Starpharma

It just does not make sense (hundreds and hundreds of millions of dollars being wasted - my opinion of course)

Oh well "Ce La Vie"



So let us see how much revenue these 3 drugs.......docetaxel, irinotecan, and cabazitaxel bring in for the big Pharma's

Docetaxel (Taxotere ® peak sales ~US$3.1B
Cabazitaxel (Jevtana ® sales were ~US$400M in 2016
Irinotecan (Camptosar® peak sales ~US$1.1B

That is a total of US$4.6 billion which when you translate it into AUD$.........(exchange rate .71).........AUD$6.47 billion

Think of these above as revenue annually.........not bad at all



As we all know these DEP ® cancer drugs (for short the 3 amigos) are in various stages of clinical trials

DEP ® DOCETAXEL PHASE 2 - to be completed by same time this year (and monetised under a license agreement with royalties....if not beforehand for the equivalent of AUD422 million)

DEP ® IRINOTECAN PHASE 1/2 - not sure when this will be completed..........however do not be surprised once results for DEP ® DOCETAXEL are published sometime in next 12 months......this DEP ® might not even advance to P2 with Starpharma. We may get an offer to license too good to refuse earlier rather than later

DEP ® IRINOTECAN going into P1 hopefully be calendar years end (depending on ethics committee approval happening before then)

Ethics plays a very important role in determining clinical trial activities

As this document below is subject to copyright, I have elected to post the link. Definitely worth a read......and you can find many more articles by searching


https://www.pfizer.com/files/research/research_clinical_trials/ethics_committee_guide.pdf[/BCOLOR]


In conclusion........ Starpharma patent portfolio currently has around 15 active patent families with over 120 granted patents and more than 30 patent applications pending.

As Jackie likes to put it

SO MUCH OPTIONALITY

I look forward to a company changing December quarter. With all the information out there........how can Starpharma be at this ridiculously low value. I mean with just the 3 Amigos......how many billion was mentioned